Rani Therapeutics Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rani Therapeutics Hldgs (RANI).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$9Upside to Avg. PT+1567.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$6
Aug 21, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$11
Aug 18, 2026	Chardan Capital	Andreas Argyrides	Initiate	Buy	$6
May 20, 2026	Canaccord Genuity	Edward Nash	Maintained	Buy	$5
Apr 1, 2026	Canaccord Genuity	Edward Nash	PT Cut	Buy	$9→$5
Mar 27, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$11
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$11
Oct 21, 2025	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$11
Oct 20, 2025	Maxim Group	Michael Okunewitch	PT Raise	Buy	$5→$10
May 16, 2025	Oppenheimer	Andreas Argyrides	PT Cut	Outperform	$14→$4
Apr 3, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$9
Feb 26, 2025	Canaccord Genuity	Edward Nash	Maintained	Buy	$9
Feb 7, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$9
Nov 19, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$9
Oct 18, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$9
Aug 16, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$13→$9
Aug 2, 2024	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$17
Jun 25, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$13
Jun 14, 2024	Maxim Group	—	Initiate	Buy	$15
Jun 13, 2024	Rodman & Renshaw	Brandon Folkes	Initiate	Buy	$10

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.

Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.

Avi Kapoor

PRO
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $9 to $5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.

Benzinga Newsdesk

Rani Therapeutics Holdings Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Rani Therapeutics Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

PRO
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

People Also Watch

People Also Watch

Rani Therapeutics Holdings Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Rani Therapeutics Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROChardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

PROCanaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

PROHC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

PROHC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

PRO
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

PRO
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target